Week of August 28, 2017 | Vol. 6, Issue 33
|
Please Note:
We have recently changed the title of our Weekly Newsletter from "Pharma And Healthcare M&A Update" to "Healthcare Trends And Transactions". The content remains the same, but we feel this title better reflects the scope of the information provided. We appreciate your continued interest in receiving weekly content on the Healthcare industry.
|
|
AstraZeneca ups investment in messenger RNA drugs with Ethris deal
Astra Zeneca spent more than $29 million on a research alliance with German biotech start-up Ethris.
AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.
In a deal with Astra and its biotech division MedImmune, Ethris will receive 25 million euros upfront, research funding and milestone payments depending on development achievements, the German group, which was founded in 2009, said on Monday. Biotech drugs commonly used today are made up of proteins produced by genetically modified rodent, bacteria or yeast cells, whereas messenger RNA drugs are designed to instruct the cells in the patient's body to produce therapeutic proteins themselves. The approach could offer a new way to tackle many hard-to-treat diseases, from cancer to infections to heart and kidney disorders. The Ethris alliance will focus on asthma and other respiratory diseases.
|
Amgen and Humana partner for improved health outcomes and efficiency
Humana Inc. and Amgen, have teamed up to identify opportunities to improve health outcomes and improve efficiency by unlocking new insights from the real world health care experiences of Humana's 13 million members.
In the collaboration agreement between Amgen and Humana, six projects are currently underway or planned, with more expected over the term of the agreement. Both organizations are committed to expanding the work into further therapeutic areas where the partnership can bring value to both Amgen and Humana. The goal is the same across all projects: deliver increased value to patients and the health care system by focusing on working to improve quality and outcomes in the context of total health care costs.
The collaboration will initially target multiple serious conditions, including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer. Researchers will combine available sources of real world evidence (RWE) with data from wearable technology, digital apps and Bluetooth-enabled drug delivery devices. Prospective observational studies are also planned. Planned research will identify patients whose serious medical conditions are likely to result in an adverse patient outcome, which may lead to development of algorithms that can predict risk and drive to early intervention. The partnership will also dive deeply into specific therapeutic areas, from defining the burden of osteoporatic fractures to understanding the impact of wearable technology on medication adherence for inflammatory diseases.
|
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts or use the download link above. Total transaction values are provided in USD millions.
|
|
|
|
Pharma & Biotech
8 transactions totaling $234 million
Supplies, Equipment & Services
15 transactions totaling $43 million
Healthcare IT & Managed Care
4 transactions totaling $1 million
Healthcare Facilities & Distributors
10 transactions totaling $457 million
|
|
|
|
|
|
Pharma & Biotech
16 private placements totaling $260 million
Supplies, Equipment & Services
14 private placements totaling $97 million
Healthcare IT & Managed Care
7 private placements totaling $14 million
Healthcare Facilities & Distributors
0 private placements
|
|
|
|
|
Pharma & Biotech
12 public offering totaling $290 million
Supplies, Equipment & Services
3 public offerings totaling $25 million
Healthcare IT & Managed Care
1 public offering totaling $1 million
Healthcare Facilities & Distributors
0 public offerings
|
 |
|
 Each week, w
e provide updated trading
comps for leading comp
anies from numerous healthcare subsectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific subsectors
For a complete trading comp analysis (including the individual equities that comprise the subsectors), click on the table to the right or use the download link from the top of this newsletter.
Note: data reflects prior week close.
|
RECENT INDUSTRY HEADLINES
A Sampling of Relevant Industry Headlines from the Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
Longevity Fund raises cash to back anti-aging startups
August 23, 2017 - Fierce Biotech
Longevity Fund has raised $22 million to make a fresh wave of investments in companies working to treat age-related diseases. The financing positions Laura Deming, who started work on the fund before turning 18, to follow up on the bets she has already placed on companies such as Unity Biotechnology. The new fund is small in size compared to many of today's biotech investment vehicles. But the track record of Deming's first, $4 million fund suggests the MIT dropout and her team will use the money to make investments in companies worth keeping tabs on.
August 22, 2017 -
Reuters
The European Commission has started an in-depth investigation of Bayer's planned $66 billion takeover of U.S. seeds group Monsanto, saying it was worried about competition in various pesticide and seeds markets.
The deal would create the world's largest integrated pesticides and seeds company, the Commission said, adding this limited the number of competitors selling herbicides and seeds in Europe.
Lilly pens deal for Evotec spinout's immune tolerance drugs
August 22, 2017 - Fierce Biotech
Eli Lilly has secured an option on immune tolerance drugs from Evotec spinout Topas Therapeutics. The multiyear agreement positions Lilly to work with Topas on candidates that convey tolerance to antigens linked to inflammation or autoimmune diseases. Topas will run preclinical proof-of-concept studies of the drugs in collaboration with Lilly in return for R&D funding. Lilly has the option to license and further develop all drug candidates generated in the collaboration. Beyond that, the publicly known details get hazy, with Topas only saying it will "participate in the future success of any compounds in-licensed by Lilly."
|
UPCOMING EVENTS
An Overview of Events Hosted or Attended by the Bourne Partners Team
|
2017 Contracting & Outsourcing Conference
September 14-15, 2017 | New Brunswick, NJ
|
7th Annual Global Healthcare Executive Summit
October 4, 2017 | Charlotte, NC
|
|
As an international, healthcare-focused merchant bank and financial advisory firm, we provide world-class services and capital to middle-market healthcare companies around the globe. We aim to keep our clients well-informed of healthcare news and events. With this additional insight in mind, together, we can recognize trends and opportunities that benefit our clients. We hope that you will reach out to Bourne Partners to help execute your healthcare operational and transactional needs. To learn more about our firm, visit our website or utilize the links below to engage with us on social media.
Sincerely,
The Bourne Partners Team
Bourne Partners
550 South Caldwell Street
Suite 900
Charlotte, NC 28202
704-552-8407
|
STAY CONNECTED
|
|
|
|
|
